Cargando…
RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity
BACKGROUND: Endocrine-resistant breast cancers have elevated expression of XBP1, where it drives endocrine resistance by controlling the expression of its target genes. Despite the in-depth understanding of the biological functions of XBP1 in ER-positive breast cancer, effectors of endocrine resista...
Autores principales: | Barua, David, Sultana, Afrin, Islam, Md Nahidul, Cox, Fergus, Gupta, Ananya, Gupta, Sanjeev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061897/ https://www.ncbi.nlm.nih.gov/pubmed/36997866 http://dx.doi.org/10.1186/s12885-023-10745-1 |
Ejemplares similares
-
XBP1 increases transactivation of somatic mutants of ESR1 and loss of XBP1 reverses endocrine resistance conferred by gain-of-function Y537S ESR1 mutation
por: Barua, David, et al.
Publicado: (2020) -
Hyperactivation of nuclear receptor coactivators induces PERK-dependent cell death
por: Hossain, Muhammad Mosaraf, et al.
Publicado: (2018) -
UPR-Induced miR-616 Inhibits Human Breast Cancer Cell Growth and Migration by Targeting c-MYC
por: Arabkari, Vahid, et al.
Publicado: (2023) -
Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance()()()
por: Putluri, Nagireddy, et al.
Publicado: (2014) -
Repression of viral gene expression and replication by the unfolded protein response effector XBP1u
por: Hinte, Florian, et al.
Publicado: (2020)